Introduction: Here we examine the relationship between achieving different levels of disease activity with tofacitinib (an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis), long-term structural progression, and patient-reported physical function. Methods: This was a post hoc analysis of two 24-month, phase III randomized controlled trials in methotrexate (MTX)-naïve (ORAL Start [NCT01039688]) or MTX-inadequate responder
disease activity (LDA) at month 6 reported normative HAQ-DI scores (\ 0.5) at month 24 than did those with CDAI MDA/HDA. Conclusion: Regardless of treatment, in both MTX-naïve and MTX-IR patients, remission or LDA at month 6 was associated with successful long-term outcomes: inhibition of structural progression and normative HAQ-DI scores. Long-term outcomes were similar when patients achieved CDAI remission or a DAS28CRP of \ 1.9, confirming that this is an appropriate cut-off for remission with DAS28CRP. Tofacitinib potentially inhibits joint damage even with persistent inflammation. Funding: Pfizer Inc.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation, pain, joint stiffness, and progressive joint destruction [1] . Patients with RA often experience impaired health-related quality of life as a result of symptoms of pain and fatigue, and loss of physical function [2, 3] . Early intervention with disease-modifying antirheumatic drugs (DMARDs) can reduce or reverse signs and symptoms of disease, inhibit progression of structural damage, and form a cornerstone of treatment [4, 5] .
Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The efficacy and safety of tofacitinib administered at doses of 5 and 10 mg twice daily (BID) either as monotherapy or in combination with conventional synthetic DMARDs, mainly methotrexate (MTX), in patients with moderately to severely active RA, have been demonstrated in phase II [6] [7] [8] [9] [10] [11] [12] and phase III [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] randomized controlled trials (RCTs) of up to 24 months' duration and in long-term extension studies with up to 105 months' observation [23, 24] . ORAL Start (NCT01039688; trial registered December 23, 2009) [18] and ORAL Scan (NCT00847613; trial registered February 17, 2009) [16] are two phase III RCTs that included radiographic outcomes. ORAL Start was conducted in MTX-naïve patients and ORAL Scan in patients who were MTX-inadequate responders (IR) [16, 18] . Patients received tofacitinib 5 or 10 mg BID as monotherapy versus MTX monotherapy (ORAL Start) or with background MTX versus placebo (ORAL Scan).
In both 24-month trials, tofacitinib improved signs and symptoms of RA and patient-reported outcomes and inhibited progression of structural damage versus comparator treatment by month 6 [16, 18, 19] . However, mean changes in van der Heijde modified total Sharp scores (mTSS) were statistically significant only with tofacitinib 10 mg BID versus placebo (tofacitinib 5 mg BID vs. placebo P = 0.079) in ORAL Scan [16] .
Here we present a post hoc analysis of data from ORAL Start and ORAL Scan which examined the efficacy of tofacitinib (vs. MTX) on long-term radiographic and Health Assessment Questionnaire-Disability Index (HAQ-DI) scores, with a particular focus on the relationship between disease activity levels at month 6 and longer-term outcomes.
METHODS

Study Design and Patients
Details of ORAL Start and ORAL Scan have been previously published [16, 18] . Eligible patients were aged C 18 years, fulfilled the American College of Rheumatology 1987 revised criteria [25] , and had active disease (C 6 tender or painful joints and C 6 swollen joints, plus C 3 distinct joint erosions, or were rheumatoid factor or anti-citrullinated antibody protein positive).
In ORAL Start, MTX-naïve patients were randomized 2:2:1 to tofacitinib 5 or 10 mg BID, or MTX starting at 10 mg per week and increasing to 20 mg per week by week 8. In ORAL Scan, MTX-IR patients were randomized 4:4:1:1 to tofacitinib 5 or 10 mg BID, placebo advanced to tofacitinib 5 mg BID, or placebo advanced to tofacitinib 10 mg BID, all with stable background MTX. Patients receiving placebo were advanced in a blinded manner to tofacitinib if they had not achieved C 20% improvement in swollen and tender joint counts after 3 months (defined as non-responders); after 6 months, all remaining placebo patients were advanced to tofacitinib.
Both studies were conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice and were approved by the Institutional Review Board at each study center. All patients provided written informed consent. This report presents post hoc analyses of data from two previously published studies [16, 18] , and additional ethics approval was not required for these analyses.
Data Analyses and Assessments
In this post hoc analysis, patients receiving tofacitinib or MTX monotherapy in ORAL Start, or tofacitinib ? MTX in ORAL Scan, were analyzed according to disease activity at month 6, which was defined by the Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints, C-reactive protein (DAS28CRP), or the DAS28-erythocyte sedimentation rate (DAS28ESR). Cut-offs utilized in this analysis using CDAI were: B 2.8 (remission); [ 2.8 to B 10 (low disease activity [LDA]); [ 10 (moderate/high disease activity [MDA/HDA]). DAS28CRP and DAS28ESR data were analyzed using the traditional cut-offs for remission, LDA, and MDA/HDA (\ 2.6; C 2.6 to B 3.2; [ 3.2, respectively), and DAS28CRP data were also analyzed using a more stringent cut-off for remission (\ 1.9). This stringent cut-off was chosen based on a recent publication examining DAS28CRP disease remission and LDA cutoffs [26] . All analyses are based on the full analysis set (randomized and received C 1 dose of study treatment) and each type of stratification (CDAI and DAS28CRP and DAS28ESR status) defined by its respective non-missing disease activity measure at month 6. Patients randomized to placebo in ORAL Scan were excluded as they advanced to tofacitinib at months 3 or 6, and only one placebo patient achieved remission at month 6.
Radiographic progression (changes from baseline in mTSS) and physical function (HAQ-DI scores) at month 24 were analyzed according to CDAI or DAS28CRP scores at month 6. Radiographic non-progression was defined as B 0 change from baseline in mTSS (non-prespecified endpoint). A normative HAQ-DI score was defined as \ 0.5.
This was an exploratory analysis; no formal statistical analyses were prespecified. Categorical endpoints were summarized by frequency (n, %). Continuous efficacy endpoints were summarized using descriptive statistics, including mean and 95% confidence intervals (CI).
The data analysis for this study was performed using SAS software, version 9.2 of the SAS System for Unix. (Copyright Ó 2008 SAS Institute Inc., Cary, NC, USA). All other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc.
RESULTS
Patients
Overall, 956 patients in ORAL Start and 797 in ORAL Scan were randomized and treated. At month 6, CDAI and DAS28CRP data were available for 1419 and 1420 patients (from both studies), respectively, all of whom were eligible for inclusion in this post hoc analysis. Baseline patient demographics and disease characteristics within the month 6 disease activity subgroups were generally similar across treatment groups (Electronic Supplementary Material Tables S1 and S2). However, in both RCTs, patients with CDAI-defined MDA/HDA at month 6 had higher baseline disease activity and mTSS than did those with LDA (without remission) or remission at month 6. Similarly, baseline disease activity was higher among patients with worse disease status at month 6 when defined by DAS28CRP (data not shown). Across disease activity groups, mean baseline mTSS were higher among patients in ORAL Scan than in ORAL Start.
Relationship Between Disease Activity at Month 6 and Month 24
The proportions of MTX-naïve patients in CDAI remission or with LDA (without remission) at month 6 were higher in those receiving both doses of tofacitinib than in those on MTX in ORAL Start, and they were generally higher in patients in ORAL Start than in those in ORAL Scan ( Table 1) . Tofacitinib treatment was also associated with lower levels of disease activity at month 6, compared with MTX, when activity was measured by the DAS28CRP. More patients achieved a DAS28CRP of \ 2.6 than CDAI remission (B 2.8), while the DAS28CRP \ 1.9 cut-off yielded similar proportions of patients to those in CDAI remission.
Relationship Between Disease Activity and Long-Term Radiographic Progression
Among patients receiving MTX monotherapy, mean change from baseline in mTSS at month 24 was smaller for patients with CDAI remission at month 6 than for patients with CDAI MDA/ HDA at month 6 ( Fig. 1a ). A similar relationship was evident for patients receiving tofacitinib 5 and 10 mg BID with or without background MTX. However, compared with MTX, less radiographic progression at month 24 was present with tofacitinib treatment in patients with MDA/HDA at month 6 ( Fig. 1a ).
For patients enrolled in ORAL Start, larger changes from baseline at month 24 in mTSS were observed in the DAS28CRP \ 2.6 category than in the category with CDAI-defined remission at month 6 ( Fig. 1b) . Patients with a DAS28CRP of \ 1.9 at month 6 generally had similar levels of changes in mTSS to those in the CDAI-defined remission category (Fig. 1b) , with the exception of patients treated with tofacitinib 10 mg BID in ORAL Scan. Irrespective of treatment, a higher number of patients in CDAI remission or LDA (without remission) at month 6 were radiographic nonprogressors at month 24 (vs. CDAI MDA/HDA), although 95% CI overlapped ( Fig. 2a) . A higher proportion of patients in the CDAI MDA/HDA category at month 6 were radiographic nonprogressors at month 24 with tofacitinib monotherapy than with MTX. In general, a DAS28CRP of \ 1.9 provided the best approximation to CDAI remission in terms of radiographic non-progression ( Fig. 2b) .
Relationship Between Disease Activity and Physical Function
Across treatment groups, there were more patients with CDAI-defined remission at month 6 or LDA who reported normative HAQ-DI scores (\ 0.5) at month 24 than there were patients with CDAI MDA/HDA (Fig. 3a) .
In ORAL Start, more patients who received tofacitinib monotherapy reported normative HAQ-DI scores at month 24 than did MTXtreated patients at month 6 with the same level of disease activity, including those with CDAI MDA/HDA at month 6, although the 95% CI overlapped (Fig. 3a ). More MTX-naïve than MTX-IR patients reported normative HAQ-DI scores.
Tofacitinib patients with a DAS28CRP of \ 2.6 at month 6 reported fewer normative HAQ-DI scores than did patients in CDAI remission and with a DAS28CRP of \ 1.9, with the exception of patients in ORAL Scan who received tofacitinib 10 mg (Fig. 3b) .
Overall, more patients who achieved CDAIdefined remission or LDA (without remission) at month 6 with tofacitinib monotherapy or with background MTX reported larger improvements from baseline in HAQ-DI scores at month 24 than did those with MDA/HDA (Fig. 4a ). Tofacitinib monotherapy was associated with numerically larger improvements in HAQ-DI scores compared with MTX within response subgroups, although the 95% CI overlapped. Improvements reported by patients with CDAI MDA/HDA at month 6 were similar with tofacitinib 5 mg BID, tofacitinib 10 mg BID, and MTX. In general, a DAS28CRP of \ 1.9 best approximated CDAI remission in terms of changes in HAQ-DI scores (Fig. 4b) .
DISCUSSION
This post hoc, exploratory analysis of data from two phase III RCTs (ORAL Start and ORAL Scan) evaluated the efficacy of tofacitinib on longterm radiographic outcomes and physical function, based on disease activity at month 6, in MTX-naïve and MTX-IR patients. Data from both RCTs were included in the analysis to explore the impact of prior MTX failure on outcomes.
CDAI-defined remission or LDA (without remission) at month 6 was associated with higher rates of radiographic non-progression at month 24 compared with MDA/HDA at month 6. This indicates that early suppression of inflammation is associated with long-term structural benefit. Compared with MTX, tofacitinib appeared to potentially inhibit joint damage even in the presence of persistent inflammation.
In this analysis, attainment of normative HAQ-DI scores and improvements in HAQ-DI from baseline at month 24 were greater in tofacitinib-or MTX-treated patients who attained remission or LDA (without remission) at month 6 than in those with MDA/HDA. This may be a direct consequence of lower disease activity or could indicate that inhibition of radiographic progression has the potential to translate into important benefits in physical function.
Comparison of outcomes from ORAL Start and ORAL Scan indicated that MTX-naïve patients treated with tofacitinib monotherapy reported greater improvement in HAQ-DI scores than MTX-IR patients receiving tofacitinib with Fig. 2 Proportion of radiographic non-progressors at month 24 according to disease activity at month 6 defined by CDAI (a) and CDAI remission, DAS28CRP \ 1.9, and DAS28CRP \ 2.6 (b). Radiographic non-progression is defined as a change in mTSS of B 0.0. BID twice daily, CDAI Clinical Disease Activity Index, CI confidence interval, DAS28CRP Disease Activity Score in 28 joints, C-reactive protein, IR inadequate responder, LDA low disease activity, MDA/HDA moderate/high disease activity, mTSS modified total Sharp score, MTX methotrexate Fig. 3 Proportion of patients reporting normative HAQ-DI scores (\ 0.5) at month 24 according to disease activity at month 6 defined by CDAI (a) and CDAI remission, DAS28CRP \ 1.9, and DAS28CRP \ 2.6 (b). Normative HAQ-DI was defined as a score of \ 0.5. BID twice daily, CDAI Clinical Disease Activity Index, CI confidence interval, DAS28CRP Disease Activity Score in 28 joints, C-reactive protein, HAQ-DI Health Assessment Questionnaire-Disability Index, IR inadequate responder, LDA low disease activity, MDA/HDA moderate/high disease activity, MTX methotrexate Fig. 4 Mean change from baseline at month 24 in HAQ-DI score according to disease activity at month 6 defined by CDAI (a) and CDAI remission, DAS28CRP \ 1.9, and DAS28CRP \ 2.6 (b). BID twice daily, CDAI Clinical Disease Activity Index, CI confidence interval, DAS28CRP Disease Activity Score in 28 joints, C-reactive protein, HAQ-DI Health Assessment Questionnaire-Disability Index, IR inadequate responder, LDA low disease activity, MDA/HDA moderate/high disease activity, MTX methotrexate background MTX. MTX-IR patients who did not achieve remission or LDA at month 6 (had MDA/HDA) appeared to be the most difficult to treat in terms of inhibiting radiographic progression and achieving important improvements in physical function by month 24, indicating that patients with already established RA may have irreversible damage and disability. It should be noted that these patients also had higher mTSS at baseline.
The relationship between disease state and subsequent long-term outcomes was generally similar whether activity at month 6 was defined by the CDAI or by the DAS28CRP. However, the choice of cut-offs to define disease states appears to be important. A DAS score of \ 2.6 has been traditionally used to define remission, whether using CRP or ESR as inflammatory markers [27] . In our analysis, patients achieved a DAS28CRP of \ 2.6 but still had residual disease activity, which yielded uncertainty in predicting long-term outcomes when it was used versus CDAI-defined remission.
In line with our findings, a DAS28CRP of \ 2.6 has been previously noted to be a less conservative measure of remission among tofacitinib-treated patients, with CDAI-defined remission rates being closer to Boolean-based remission rates [28] ; other cut-offs for DAS28CRP remission and LDA have been proposed [26] . DAS28CRP has also been reported to result in higher remission rates than DAS28ESR when a score of \ 2.6 is used for both [26] . When ORAL Start and ORAL Scan data were analyzed by more stringent DAS28CRP cut-offs, a DAS28CRP of \ 1.9 consistently produced results most similar to CDAI-defined remission. A DAS28CRP of \ 1.9 was also found to be similar to CDAI remission when analyzing data from etanercept clinical trials [26] . The data from ORAL Start and ORAL Scan were also analyzed by DAS28ESR-defined disease status (data not presented here), and when remission was defined as a DAS28ESR of \ 2.6, findings were more similar to CDAI remission and a DAS28CRP of \ 1.9 than a DAS28CRP of \ 2.6.
Potential limitations of the present analysis include the post hoc exploratory nature of this evaluation. Patient numbers in some of the subgroups were small, potentially resulting in higher data variability and, therefore, in wide 95% CI. In addition, the comparability of the level of disease activity across the disease activity groups cannot be confirmed.
CONCLUSIONS
Overall, attainment of remission or LDA at month 6, regardless of treatment, provides the best probability of long-term inhibition of radiographic progression of structural damage and important improvements in physical function. However, treatment with tofacitinib resulted in reduced structural progression at month 24 compared with treatment with MTX, even in patients with MDA/HDA at month 6, indicating a partial dissociation between inflammatory disease and joint damage in patients treated with tofacitinib. Long-term outcomes were similar when patients achieved CDAI remission or a DAS28CRP of\ 1.9, confirming that this should be the new remission cut-off when utilizing DAS28CRP in clinical practice.
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